Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Rationale for targeting FPR2 in female patients with pancreatic cancer

Dhifaf Sarhan • 12 Nov 2021
SITC 2021
Pancreatic Cancer

Dhifaf Sarhan, PhD, Karolinska Institute, Stockholm, Sweden, discusses the rationale for targeting FPR2 in female patients with pancreatic cancer. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Dhifaf Sarhan

1:20
Differences in tumor microenvironment between female and male patients with pancreatic cancer
Dhifaf Sarhan • 12 Nov 2021
0:43
Importance of patient's gender when developing personalised immunotherapy
Dhifaf Sarhan • 12 Nov 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:16
Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti • 9 Apr 2024
0:40
The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese • 8 Apr 2024
0:48
Siltuximab and spartalizumab in advanced pancreatic adenocarcinoma
Olatunji Alese • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals